Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for rare genetic diseases. Co.'s clinical programs consist of: EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. Co. has other AAV-based gene therapies in developmental stages designed to treat the CLN1 and CLN3 forms of Batten Disease, cystic fibrosis and retinal diseases. Co. is also developing AAV-based gene therapies through its AIM™ capsid platform and internal AAV vector research programs. We show 29 historical shares outstanding datapoints in our coverage of ABEO's shares outstanding history.
Understanding the changing numbers of ABEO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABEO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABEO by allowing them to research ABEO shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
